Thermo Fisher Scientific, the world leader in serving science, today announced an exclusive distribution agreement with Aesku.Group (Aesku), a leading provider of innovative diagnostic solutions, to market, sell, and support their portfolio of FDA-Cleared IFA products, automated instruments, and software in the United States. With this agreement, Thermo Fisher positions itself to offer laboratories a comprehensive suite of automated diagnostic systems and methodologies available in the U.S. market.
By expanding its immunology product portfolio of EliA autoimmune diagnostics, ImmunoCAP™ allergy diagnostics, and Phadia Laboratory Systems with complimentary reagents and systems from Aesku, Thermo Fisher will continue to meet the evolving needs of laboratories and healthcare professionals, enabling faster and more accurate diagnoses for patients.
"Our partnership with Aesku underscores our commitment to enabling our customers to make the world healthier by providing innovative solutions that help advance the detection and diagnosis of complex autoimmune diseases," stated Santhosh Nair, president of ImmunoDiagnostics, Thermo Fisher Scientific. “Aesku has pioneered innovative and efficient solutions that synergize seamlessly with our existing portfolio. We are excited about offering these solutions to our customers and the opportunity to positively impact more patient lives.”
Under the agreement, Thermo Fisher will engage in sales and marketing, as well as related activities, for Aesku products exclusively in the United States. Thermo Fisher will also provide installation, maintenance, and support services to customers in the United States. Aesku will continue to manufacture all products under the agreement.
Dr. Torsten Matthias, President and founder of Aesku said, “we are thrilled to enter this partnership with Thermo Fisher Scientific, a global diagnostics powerhouse, to bring our pioneering IFA solutions to the forefront of the U.S. market. Aesku’s commitment to innovation in autoimmune diagnostics aligns seamlessly with Thermo Fisher’s Mission of enabling customers to make the world healthier, cleaner and safer. Together, we are setting new benchmarks for accuracy and efficiency in autoimmunity testing, ensuring clinicians and patients receive the most advanced diagnostic capabilities available.”
For more information on Immunology solutions from Thermo Fisher Scientific, please visit https://www.thermofisher.com/phadia.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
About Aesku.Group
Aesku.Group, based in Wendelsheim, Germany, is a research-focused supplier of innovative and efficient products and services for the early detection, diagnosis and prognosis of autoimmune diseases. Since its foundation in the year 2000 Aesku.Diagnostics has become a recognized name in the field of autoimmunity for launching over 150 different products together with uninterrupted services in more than 90 countries worldwide. Since then Aesku.Group simplifies the lab routine with accurate, robust and reliable tests, laying equal emphasis on all major disease sectors, the company has earned a solid reputation in autoimmune diagnostics.
Die Aesku.Group mit Sitz in Wendelsheim, ist ein forschungsorientierter Anbieter von innovativen und effizienten Produkten und Dienstleistungen, zur Früherkennung, Diagnose und Prognose von Autoimmun- & Infektionserkrankungen, Allergien und Nahrungsmittelunverträglichkeiten.
Das Unternehmen vereinfacht die Laborroutine mit präzisen, robusten und zuverlässigen Tests.
Die hohe Qualität und der Innovationsvorsprung aller Aesku® Produkte basiert auf der hauseigenen Forschung, Entwicklung und Produktion der Aesku® Tests, Laborautomaten und Laborsoftware.
Zurzeit beschäftigt die Aesku.Group rund 300 Mitarbeiter aus 20 Nationen, und bietet über 1000 verschiedene Produkte an, welche in über 90 Ländern vertrieben werden. Aesku.Group hat lokale Niederlassungen in Deutschland, den USA, Italien, Großbritannien, Singapur, Kolumbien und China.
Heute ist die Aesku.Group eine Firmengruppe, zu der Aesku.Diagnostics (IVD in Autoimmunität und Infektionsserologie), Aesku.Therapy (Autoimmuntherapien), Aesku.Systems (Laborautomatisierung & Software), Aesku.Kipp Institute (Internationale Forschungskooperation), Aesku.DST (Allergie und Lebensmittelunverträglichkeitstests) & Aesku.Bion (Immunologie, Virologie und Mikrobiologie) und die Tochtergesellschaften Aesku.Inc (US Vertrieb) gehören.
Neben dem eigenen herausragenden Engagement für Forschung und Entwicklung initiierte und unterstützt Aesku.Diagnostics das Aesku.Kipp Institute, eine gemeinnützige Organisation, die sich vor allem mit Grundlagenforschung und interdisziplinärem Wissenstransfer im Bereich der Autoimmunität beschäftigt.
AESKU.GROUP GmbH
Mikroforum Ring 2
55234 Wendelsheim
Telefon: +49 (6734) 9622-0
Telefax: +49 (6734) 9622-2222
http://www.aesku.com
Marketing Kommunikation
Telefon: +49 (6734) 9622-0
Fax: +49 (6734) 9622-2222
E-Mail: presse@aesku.com
